Sangamo Therapeutics, Inc. (SGMOQ)
0.171
+0.01
(+4.27%)
USD |
OTCM |
Sep 02, 16:00
Sangamo Therapeutics Research and Development Expense (TTM) : 113.79M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 113.79M |
| December 31, 2025 | 112.67M |
| September 30, 2025 | 104.77M |
| June 30, 2025 | 108.19M |
| March 31, 2025 | 105.85M |
| December 31, 2024 | 115.68M |
| September 30, 2024 | 143.35M |
| June 30, 2024 | 171.22M |
| March 31, 2024 | 205.42M |
| December 31, 2023 | 233.36M |
| September 30, 2023 | 248.33M |
| June 30, 2023 | 253.46M |
| March 31, 2023 | 254.53M |
| December 31, 2022 | 249.90M |
| September 30, 2022 | 235.52M |
| June 30, 2022 | 232.90M |
| March 31, 2022 | 232.97M |
| December 31, 2021 | 230.82M |
| September 30, 2021 | 231.38M |
| June 30, 2021 | 214.16M |
| March 31, 2021 | 195.60M |
| December 31, 2020 | 180.65M |
| September 30, 2020 | 166.62M |
| June 30, 2020 | 157.62M |
| March 31, 2020 | 152.55M |
| Date | Value |
|---|---|
| December 31, 2019 | 145.92M |
| September 30, 2019 | 140.85M |
| June 30, 2019 | 133.37M |
| March 31, 2019 | 126.17M |
| December 31, 2018 | 114.87M |
| September 30, 2018 | 100.99M |
| June 30, 2018 | 90.60M |
| March 31, 2018 | 76.33M |
| December 31, 2017 | 65.73M |
| September 30, 2017 | 60.24M |
| June 30, 2017 | 58.82M |
| March 31, 2017 | 63.29M |
| December 31, 2016 | 65.62M |
| September 30, 2016 | 71.63M |
| June 30, 2016 | 71.32M |
| March 31, 2016 | 67.48M |
| December 31, 2015 | 67.20M |
| September 30, 2015 | 62.28M |
| June 30, 2015 | 61.88M |
| March 31, 2015 | 59.69M |
| December 31, 2014 | 56.74M |
| September 30, 2014 | 52.53M |
| June 30, 2014 | 44.94M |
| March 31, 2014 | 40.79M |
| December 31, 2013 | 36.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Anixa Biosciences, Inc. | 4.557M |
| Vicapsys Life Sciences, Inc. | 0.0043M |